EDP-239 / Enanta Pharma - LARVOL DELTA

Enanta's lead NS5A inhibitor candidate for HCV, EDP-239 selected as one of Windhover's top 10 infectious disease projects to watch (PRNewswire) - EDP-239, has selected by Windhover among top 10 interesting infectious disease projects to watch; Enanta to initiate a P1 trial for EDP-239 in the coming months, following preclinical studies that demonstrated picomolar potency against multiple genotypes of the virus, an excellent safety profile & a preclinical PK profile amenable to OD dosing in humans

Anticipated P1 trial initiation • Hepatitis C Virus

Two-way Interaction Between Alisporivir and EDP239 (clinicaltrials.gov) - P1; N=42; Completed; Sponsor: Enanta Pharmaceuticals; Recruiting -> Completed

Trial completion • Biosimilar • Hepatitis C Virus • Immunology • Inflammation

Enanta Pharmaceuticals’ HCV NS5A inhibitor EDP-239 advances into combination studies with alisporivir (DEB025) (Enanta Press Release) - P1, N=42; NCT02173574; Sponsor: Novartis; "Enanta...announced that Novartis has advanced EDP-239...into drug combination studies with alisporivir (DEB025)....The phase 1 combination study conducted by Novartis is investigating the pharmacokinetics, safety, and tolerability of alisporivir (DEB025) and EDP-239 when co-administered to healthy adult subjects and is scheduled to enroll 42 healthy subjects."

New P1 trial • Hepatitis C Virus